Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease

Description

The purpose of this study is to determine how inflammation is related to other changes in the brain that occur during the progression of Alzheimer's disease. The investigators are also studying how inflammation is related to the symptoms that first occur in patients with Alzheimer's disease (AD). For this reason, the investigators are asking people with different versions of Alzheimer's disease and/or other related dementias to participate. This includes patients with: * Mild Cognitive Impairment * Posterior cortical atrophy - a version of Alzheimer's disease with vision difficulties * Logopenic variant primary progressive aphasia - a version of Alzheimer's disease with language difficulties * Amnestic Alzheimer's disease - a "typical" version of Alzheimer's disease with memory difficulties * The investigators are also enrolling older adults with normal visual, language, and memory function.

Conditions

Alzheimer Disease

Study Overview

Study Details

Study overview

The purpose of this study is to determine how inflammation is related to other changes in the brain that occur during the progression of Alzheimer's disease. The investigators are also studying how inflammation is related to the symptoms that first occur in patients with Alzheimer's disease (AD). For this reason, the investigators are asking people with different versions of Alzheimer's disease and/or other related dementias to participate. This includes patients with: * Mild Cognitive Impairment * Posterior cortical atrophy - a version of Alzheimer's disease with vision difficulties * Logopenic variant primary progressive aphasia - a version of Alzheimer's disease with language difficulties * Amnestic Alzheimer's disease - a "typical" version of Alzheimer's disease with memory difficulties * The investigators are also enrolling older adults with normal visual, language, and memory function.

Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease

Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease

Condition
Alzheimer Disease
Intervention / Treatment

-

Contacts and Locations

New York

Columbia University Irving Medical Center, New York, New York, United States, 10032

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Age 50 and over at time of screening.
  • 2. At screening, must have no cognitive impairment, or meet criteria for amnestic Alzheimer's disease, posterior cortical atrophy, or logopenic variant primary progressive aphasia. Diagnoses will be made based on history, exam, neuropsychological testing, brain MRI, and consensus diagnosis.
  • 3. Patients must have Clinical Dementia Rating scale score of 0.5 or 1 at enrollment. Controls must have Clinical Dementia Rating scale score of 0 at enrollment.
  • 4. Subjects unable to provide informed consent must have a surrogate decision maker.
  • 5. Written and oral fluency in English or Spanish.
  • 6. Able to participate in all scheduled evaluations and to complete all required tests and procedures.
  • 7. In the opinion of the PI, the subject must be considered likely to comply with the study protocol and to have a high probability of completing the study.
  • 1. Past or present history of a brain disorder other than Alzheimer's disease (including presence of cortical infarct on MRI even in absence of clinical stroke).
  • 2. Serious medical conditions, which make study procedures of the current study unsafe. Such serious medical conditions include uncontrolled epilepsy and multiple serious injuries.
  • 3. Contraindication to MRI scanning.
  • 4. Conditions precluding entry into the scanners (e.g. morbid obesity, claustrophobia, etc.).
  • 5. Exposure to research related radiation in the past year that, when combined with this study, would place subjects above the allowable limits.
  • 6. Exact medication exclusions are up to the discretion of the PI in consultation with the MD liaison.

Ages Eligible for Study

50 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Patrick Lao,

Patrick J. Lao, PhD, PRINCIPAL_INVESTIGATOR, Columbia University

Study Record Dates

2026-05-31